Safety and efficacy of topically administered netarsudil‐latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG)

Abstract

Objective The aim of the study was to evaluate safety and efficacy of topically administered 0.02% netarsudil‐0.005% latanoprost fixed‐dose combination (FDC) (Rocklatan™; Aerie Pharmaceutical) in normal and glaucomatous dogs with ADAMTS10‐open‐angle glaucoma (ADAMTS10‐OAG). Animals studied Five normal and five glaucomatous beagle dogs with ADAMTS10‐OAG were the study animals. Procedures In each dog, left (OS) or right eye (OD) was randomly selected for netarsudil‐latanoprost FDC treatment. Contralateral eyes served as latanoprost‐treated controls. The study was divided into four consecutive study periods: following a 4‐day baseline period, two sequential 8‐day study periods followed with once daily (q24h) and twice daily (q12h) treatments and ending with a washout period. Efficacy was measured by diurnal intraocular pressure (IOP) and pupil diameter. Safety was assessed by routine ophthalmic examination, gonioscopy, and pachymetry. Differences in least square means of quantitative outcome measures were compared between FDC and latanoprost treatments by using the linear Gaussian model. Results Baseline IOPs were 13.6 ± 0.7 mmHg (mean ± SEM) in normal and 28.3 ± 1.4 mmHg in OAG‐affected dogs. There was a significant decrease in mean diurnal IOP following FDC administration in both normal (q24h: −2.1 mmHg; q12h: −4.1 mmHg) and glaucomatous dogs (q24h: −14.2 mmHg; q12h: −17.7 mmHg; p < .0001). There was no significant difference in the treatment effect when comparing FDC to latanoprost. Both FDC and latanoprost administration resulted in similarly significant pupil constriction (p < .0001). The FDC administration was well‐tolerated but resulted in conjunctival hyperemia. Conclusions Once or twice daily administration of netarsudil‐latanoprost FDC (Rocklatan™) and latanoprost was equally effective in lowering IOP in normal and OAG‐affected dogs. There was no netarsudil‐related added treatment effect.

Comparison of three rebound tonometers in normal and glaucomatous dogs

“…All the data was collected over the course of 2 weeks and between F I G U R E 1 Use of the iCare rebound tonometers TonoVet® (A) and TonoVet Plus® (B) in dogs 7 Am and 11 Am. Since diurnal rebound tonometry by use of TV is routinely performed as part of dog colony management and specific IOP studies, 29,30 all animals were well adjusted to the experimental setup. The nine ADAMTS10-OAG-affected dogs (17 eyes) receiving IOP-lowering glaucoma medications had their IOPs taken twice-once on normal dosing and once with a skipped dose-resulting in 116 measurements from 99 eyes.…”

Assessment of Early Glaucomatous Optic Neuropathy in the Dog by Spectral Domain Optical Coherence Tomography (SD-OCT)

“…At the end of the SD-OCT sessions, the stay sutures were removed, and the animals were allowed to awaken under close supervision. Drug-induced mydriasis was reversed in ADAMTS10 -mutants with topical 0.005% latanoprost ophthalmic solution (Greenstone LLC., Peapack, NJ, USA) [ 25 ].…”

“…animals were allowed to awaken under close supervision. Drug-induced mydriasis was reversed in ADAMTS10-mutants with topical 0.005% latanoprost ophthalmic solution (Greenstone LLC., Peapack, NJ, USA) [25]. One masked investigator (AO) analyzed the cSLO image and SD-OCT scans through the HRA/Spectralis ® Viewing Module (version 5.4.6.0) and ImageJ (NIH ImageJ; NIH, Bethesda, MD).…”